Correcting for batch effects in case-control microbiome studies

High-throughput data generation platforms, like mass-spectrometry, microarrays, and second-generation sequencing are susceptible to batch effects due to run-to-run variation in reagents, equipment, protocols, or personnel. Currently, batch correction methods are not commonly applied to microbiome se...

Full description

Saved in:
Bibliographic Details
Published in:PLoS computational biology Vol. 14; no. 4; p. e1006102
Main Authors: Gibbons, Sean M, Duvallet, Claire, Alm, Eric J
Format: Journal Article
Language:English
Published: United States Public Library of Science 23-04-2018
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-throughput data generation platforms, like mass-spectrometry, microarrays, and second-generation sequencing are susceptible to batch effects due to run-to-run variation in reagents, equipment, protocols, or personnel. Currently, batch correction methods are not commonly applied to microbiome sequencing datasets. In this paper, we compare different batch-correction methods applied to microbiome case-control studies. We introduce a model-free normalization procedure where features (i.e. bacterial taxa) in case samples are converted to percentiles of the equivalent features in control samples within a study prior to pooling data across studies. We look at how this percentile-normalization method compares to traditional meta-analysis methods for combining independent p-values and to limma and ComBat, widely used batch-correction models developed for RNA microarray data. Overall, we show that percentile-normalization is a simple, non-parametric approach for correcting batch effects and improving sensitivity in case-control meta-analyses.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
I have read the journal's policy and the authors of this manuscript have the following competing interests: EJA is a co-founder of Finch Therapeutics, a microbiome therapeutics company.
ISSN:1553-7358
1553-734X
1553-7358
DOI:10.1371/journal.pcbi.1006102